Business Wire

Great Northern Hydroponics Projects CA$150,000 in Annual Savings After Fluence LED Implementation

9.2.2021 16:00:00 EET | Business Wire | Press release

Share

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial food and cannabis production, and Great Northern Hydroponics, an Ontario, Canada-based greenhouse growing more than 10 varieties of tomatoes, announced today that the companies’ collaborative LED implementation is projected to save an estimated 150,000 Canadian dollars in annual operating costs for the greenhouse. The project also qualified for an incentive through the Independent Electricity System Operator’s (IESO) Save on Energy Retrofit program that will significantly reduce the upfront costs of upgrading its lighting technology.

Great Northern Hydroponics’ 70-acre facility produces 20 million pounds of premium tomatoes annually. Its hydroponic greenhouses create optimum growing conditions through a sophisticated climate control system as well as a biologically controlled environment to prevent pest manifestations. Fluence’s LED technology was retrofitted across 10 acres of the facility’s tomato glasshouse. At the helm of Great Northern Hydroponics’ growing operation are Guido van het Hof, the company’s president and general manager, and Dean Bernardes, vice president of operations. Both hold decades of experience growing high-quality crops using the industry’s most advanced cultivation technology.

“We’ve been growing tomatoes for more than 20 years,” Van het Hof said. “As one of the first growers in our region to illuminate crops in a commercial environment, we’ve been immersed in researching and optimizing spectral strategies for plant growth and quality. Since the onset of LED technology, I’ve been particularly curious about how broad-spectrum LEDs could affect plant development. Based on our years of research and trialing, we’ve discovered that crops grow beautifully—with higher yields and fruit weights—under broad-spectrum light.”

Van het Hof’s multiyear commitment to researching the latest advancements and strategies for LED horticulture lighting rivals leading research universities and some of the world’s largest cultivators. In his pursuit to identify the optimal spectral strategy for vine crop production, Van het Hof spearheaded various trials with high-pressure sodium fixtures as well as LED technology. Throughout his decade-long exploration, Van het Hof has recorded significant advantages under broad-spectrum LED technology, reporting an increase in biomass and fruit production as well as significant energy savings—reductions which enabled the Great Northern Hydroponics team to leverage the Save on Energy Retrofit program offering growers incentives for energy-efficient lighting upgrades.

“Great Northern Hydroponics has always been a pioneer in leveraging horticulture technology and innovative cultivation methods,” said Steve Graves, vice president of business development for Fluence and long-time collaborator with Van het Hof. “Our work with Guido has informed some of our most important product advancements for vine crop growers throughout the world. Guido and his team at Great Northern Hydroponics have reinforced the validity and efficacy of LED lighting in greenhouse environments.”

Through Fluence’s utility rebate coordination program, the company assists growers with identifying, applying for and, in some cases, creating rebate programs in a facility’s respective region. With Great Northern Hydroponics’ lighting upgrade supported by the Save on Energy Retrofit program incentive, Van het Hof estimates the business will save approximately CA$150,000 in annual operational costs by replacing its high-pressure sodium lighting with Fluence’s LED technology.

“LED technology is proving to be superior across all categories,” Van het Hof added. “Our plants are flourishing under broad-spectrum lighting, our operational costs are decreasing and our staff is enjoying working with white light versus harsher, redder lights. It’s a win-win for everyone.”

For more information on Fluence and its rebate services, visit www.fluence.science.

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fluence,
Emma Chase
emma@redfancommunications.com
C: 512-917-4319

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye